TY - JOUR
T1 - Brain and spinal cord distribution of biphalin
T2 - Correlation with opioid receptor density and mechanism of CNS entry
AU - Abbruscato, Thomas J.
AU - Thomas, Sarah A.
AU - Hruby, Victor J.
AU - Davis, Thomas P.
PY - 1997/9
Y1 - 1997/9
N2 - Biphalin [(Tyr-D-Ala-Gly-Phe-NH)2] is a bivalent, opioid peptide containing two pharmacophores linked by a hydrazine bridge. When administered intracerebroventricularly, it has been shown to be more potent than morphine and etorphine at eliciting antinociception. Biphalin has also been shown to cross both the blood-brain and blood-cerebrospinal fluid barriers. To understand the basis of biphalin's potency, regional brain and spinal cord distribution studies with [125I-Tyr1]biphalin were performed 5, 20, and 40 min after intravenous bolus injections. A statistically greater amount of [125I-Tyr1]-biphalin was detected in the nucleus accumbens compared with other brain regions (p < 0.05). This correlates with the high density of δ- and μ-opioid receptor mRNA and binding sites shown to be expressed in the nucleus accumbens. Also, a statistically greater amount of [125I-Tyr1] biphalin was detected in two other circumventricular organs, the choroid plexus and pituitary, when compared with other brain regions. These studies provide evidence that biphalin can reach not only brain sites, but also spinal sites to elicit antinociception. The overall CNS distribution of [125I-Tyr1]biphalin was decreased with naloxone, D-Phe-Cys-Tyr-D-Trp- Arg-Thr-Pen-Thr-NH2, or naltrindole pretreatment, showing that biphalin detected in the brain and spinal cord is binding to δ- and μ-opioid receptors. Additional in situ brain perfusion experiments identified a saturable component contributing to CNS entry of [125I-Tyr1]biphalin, which could be described by Michaelis-Menten kinetics with a K(m) of 2.6 ± 4.8 μM, V(max) of 14.6 ± 2.89 pmol-1 · min-1 · g-1 and K(d) of 0.568 ± 0.157 μl · min-1 · g-1. Brain entry of [125-Tyr1]biphalin was sensitive to 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid and L- phenylalanine, suggesting use of the large neutral amino acid carrier. This work provides evidence that biphalin is a promising, potent analgesic that has a unique mechanism for reaching both spinal and supraspinal opioid receptor sites.
AB - Biphalin [(Tyr-D-Ala-Gly-Phe-NH)2] is a bivalent, opioid peptide containing two pharmacophores linked by a hydrazine bridge. When administered intracerebroventricularly, it has been shown to be more potent than morphine and etorphine at eliciting antinociception. Biphalin has also been shown to cross both the blood-brain and blood-cerebrospinal fluid barriers. To understand the basis of biphalin's potency, regional brain and spinal cord distribution studies with [125I-Tyr1]biphalin were performed 5, 20, and 40 min after intravenous bolus injections. A statistically greater amount of [125I-Tyr1]-biphalin was detected in the nucleus accumbens compared with other brain regions (p < 0.05). This correlates with the high density of δ- and μ-opioid receptor mRNA and binding sites shown to be expressed in the nucleus accumbens. Also, a statistically greater amount of [125I-Tyr1] biphalin was detected in two other circumventricular organs, the choroid plexus and pituitary, when compared with other brain regions. These studies provide evidence that biphalin can reach not only brain sites, but also spinal sites to elicit antinociception. The overall CNS distribution of [125I-Tyr1]biphalin was decreased with naloxone, D-Phe-Cys-Tyr-D-Trp- Arg-Thr-Pen-Thr-NH2, or naltrindole pretreatment, showing that biphalin detected in the brain and spinal cord is binding to δ- and μ-opioid receptors. Additional in situ brain perfusion experiments identified a saturable component contributing to CNS entry of [125I-Tyr1]biphalin, which could be described by Michaelis-Menten kinetics with a K(m) of 2.6 ± 4.8 μM, V(max) of 14.6 ± 2.89 pmol-1 · min-1 · g-1 and K(d) of 0.568 ± 0.157 μl · min-1 · g-1. Brain entry of [125-Tyr1]biphalin was sensitive to 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid and L- phenylalanine, suggesting use of the large neutral amino acid carrier. This work provides evidence that biphalin is a promising, potent analgesic that has a unique mechanism for reaching both spinal and supraspinal opioid receptor sites.
KW - Biphalin
KW - Blood-brain barrier
KW - Cerebrospinal fluid
KW - Kinetics
KW - Opioid
KW - Saturation
KW - Spinal cord
KW - Transport
UR - http://www.scopus.com/inward/record.url?scp=0030742898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030742898&partnerID=8YFLogxK
U2 - 10.1046/j.1471-4159.1997.69031236.x
DO - 10.1046/j.1471-4159.1997.69031236.x
M3 - Article
C2 - 9282948
AN - SCOPUS:0030742898
SN - 0022-3042
VL - 69
SP - 1236
EP - 1245
JO - Journal of neurochemistry
JF - Journal of neurochemistry
IS - 3
ER -